CTC study in lung cancer screening breakthrough
15 February 2021
The major London lung cancer screening study SUMMIT has announced findings with potentially huge implications for the treatment of lung cancer in the UK. 

Coordinated by the CR UK and UCL Cancer Trials Centre, the study has so far detected 180 lung cancers via CT scan among its participants. Crucially, 70% of these cancers were found at an early stage, when chances of successful treatment are much greater than with a later diagnosis.

Speaking to The Guardian, SUMMIT's chief investigator Professor Sam Janes explained the significance of the results: ‘In my lung cancer clinic at UCLH, seven out of 10 people have cancer that’s been inoperable, incurable, from the first time they saw a doctor. Whereas with the cancers that we see with Summit, seven out of 10 are potentially curable, because they were detected earlier.’

SUMMIT is designed for participants living in London whose smoking history puts them at a higher risk of developing cancer. So far, over 12,000 Londoners between the ages of 50 and 77 have taken part, undergoing a lung health checkwhich involves the CT scan responsible for detecting the cancerand giving a blood sample for clinical evaluation. 

Lung cancer is currently the deadliest form of the disease in the UK, responsible for around 35,000 deaths per year.

The full story can be read over at The GuardianSUMMIT is delivered by the UCLH Cancer Collaborative in close collaboration with UCL, and GRAIL, a US healthcare company focused on the early detection of lung cancer. More information can be found on the study’s website.
Contact Us
Cancer Research UK & UCL Cancer Trials Centre
University College London
90 Tottenham Court Road

View map
+44 (0)20 7679 9898 (General CTC Enquiries)
020 7679 9899
University College London, Gower Street, London, WC1E 6BT +44 (0)20 7679 2000

Copyright © 2024 UCL | Disclaimer | Freedom of Information | Accessibility | Privacy | Cookies | Contact Us